Novo’ Nordisk’s drug to cut kidney disease advance in diabetics gets nod
Novo Nordisk’s medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Novo Nordisk’s medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular.
Zimmer Biomet Holdings, Inc., a US medical device maker, will acquire Paragon 28 Inc., for $1.1 billion to expand into musculoskeletal care, according.
A US government’s decision to pause funding for HIV programmes in low and middle-income countries will take the world back to the 1980s.
Anglo-Swedish AstraZeneca Plc., and Japan’s Daiichi Sankyo’s therapy to treat a certain form of breast cancer has been approved by the US drug.
Biogen Inc. and its Japanese partner, Eisai Co. Ltd., announced that the US regulator had approved four-weekly maintenance dosing for its Alzheimer's drug.
HQ Team January 26, 2025: Scientists from Delft University of Technology, Vienna Biocenter, and Lausanne have discovered that Structural Maintenance of Chromosomes (SMC).
HQ Team January 26, 2025: Over 73 people are down with Guillain Barre Syndrome (GBS), a rare nerve disorder, in Pune city in.
HQ Team January 24, 2025: A recent study led by Empa researchers has developed a new mathematical model that improves predictions of how.
HQ Team January 24, 2025: A comprehensive genome-wide association study (GWAS) has found 298 regions containing DNA variations for increased risk of bipolar.
Hyundai ADM Bio, a subsidiary of South Korea’s Hyundai Bioscience, unveiled an oral cancer drug that allows patients to make a shift from intravenous.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com